GE HealthCare agreed to acquire Sofie Biosciences for $945 million in cash, aiming to expand its US footprint in radiopharmaceutical manufacturing and distribution for PET tracers. The deal is expected to close in the first half of 2027 and would bring Sofie’s contract manufacturing network into GE HealthCare’s pharmaceutical diagnostics business. The acquisition strengthens access to F18-labeled PET products that require time-sensitive production and distribution, including GE HealthCare’s Flyrcado. GE HealthCare also said it will gain rights to FAPI-74, a pan-cancer PET radiotracer outside the US. Operationally, the transaction could reduce bottlenecks in radiopharmaceutical adoption by increasing capacity across 15 US CMO sites while preserving Sofie’s role as a manufacturing partner for customers during and after the transition.